464 top medical experts on Histiocytosis across 48 countries and 30 U.S. states, including 334 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Histiocytosis: General term for the abnormal appearance of histiocytes in the blood. Based on the pathological features of the cells involved rather than on clinical findings, the histiocytic diseases are subdivided into three groups: histiocytosis, langerhans cell; histiocytosis, NON-langerhans-cell; and histiocytic disorders, malignant.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Lymphatic Diseases (4,615) and Narrower Categories: Langerhans-Cell Histiocytosis (1,438), Malignant Histiocytic Disorders (280), Non-Langerhans-Cell Histiocytosis (893).
  4. Clinical Trials ClinicalTrials.gov : at least 72 including 13 Active, 17 Completed, 26 Recruiting


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Diamond, Eli L   Neurology   ClinicalTrials.gov Google Publications
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. . Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Relevant US NIH Grant Funding: $1,093,942 over the last 5 years
    Disclosed payments in 2021 from 2 biomedical companies, totalling $1,270, including $1,270 from  PFIZER INC.
    Subjects: Mutation; Proto-Oncogene Proteins B-raf; Histiocytic Disorders, Malignant; Anaplastic Lymphoma Kinase; Antineoplastic Agents
    Categories: Genetics; Therapeutic Use; Drug Therapy; Enzymology; Antagonists & Inhibitors
    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015)
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)

  2. Hyman, David M   Medical Oncology   Google Publications
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Subjects: Mutation; Proto-Oncogene Proteins B-raf; Histiocytic Disorders, Malignant; Anaplastic Lymphoma Kinase; Antineoplastic Agents
    Categories: Genetics; Therapeutic Use; Drug Therapy; Enzymology; Antagonists & Inhibitors
    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015)
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)

  3. Lacouture, Mario E   Dermatology  Google Publications
    Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 2007)
    Medicare Accepted
    Disclosed payments in 2021 from 14 biomedical companies, totalling $43,873, including $14,725 from  Novartis Pharmaceuticals Corporation
    Subjects: Histiocytic Disorders, Malignant; Mutation; Proto-Oncogene Proteins B-raf; Anaplastic Lymphoma Kinase; Azetidines
    Categories: Genetics; Therapeutic Use; Drug Therapy; Enzymology; Antagonists & Inhibitors
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)
    Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. (2019)

  4. Rampal, Raajit   Medical Oncology  Google Publications
    Weill Cornell Medical College, New York, NY, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 9 biomedical companies, totalling $12,795.5, including $5,265.5 from  Incyte Corporation
    Subjects: Histiocytic Disorders, Malignant; Mutation; Proto-Oncogene Proteins B-raf; Azetidines; Imidazoles
    Categories: Therapeutic Use; Drug Therapy; Genetics; Enzymology; Antagonists & Inhibitors
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)
    Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. (2015)

  5. Allen, Carl E   Pediatric Hematology-Oncology  ClinicalTrials.gov Google Publications
    Baylor College of Medicine, Texas Childrens Hospital, Texas Childrens Cancer Center, Houston, TX; and. Top Hospital
    Physician  Highly Published  Case Reports 
    Relevant US NIH Grant Funding: $1,665,343 over the last 5 years
    Disclosed payments in 2021 from 2 biomedical companies, totalling $5,700, including $5,700 from  Sobi, Inc
    Subjects: Dendritic Cells; Lung Diseases; Magnetic Resonance Imaging; Pneumothorax; Positron Emission Tomography Computed Tomography
    Categories: Therapy; Pathology; Diagnosis; Diagnostic Imaging
    Updates on histiocytic disorders. (2014)
    Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. (2013)

  6. Khoury, Joseph D   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
    Physician  Highly Published  Case Reports 
    Medical school: Other (MD, 1997)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Breast; Hematologic Neoplasms; Inclusion Bodies; Lymphoma; Lymphoma, B-Cell
    Categories: Pathology; Complications; Etiology
    Crystal-storing histiocytosis: a clinicopathological study of 13 cases. (2016)
    Unusual breast mass: lymphoma with crystal-storing histiocytosis. (2015)

  7. Dogan, Ahmet   Clinical Pathology/Laboratory Medicine  Google Publications
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Other (MD, 1984)
    Medicare Accepted
    Subjects: Histiocytic Disorders, Malignant; Paraproteinemias; Azetidines; Brain Diseases; Imidazoles
    Categories: Pathology; Therapeutic Use; Complications; Drug Therapy; Enzymology; Etiology
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)
    Crystal-storing histiocytosis: a clinicopathological study of 13 cases. (2016)

  8. Arcila, Maria E   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician 
    Disclosed payments in 2021 from 5 biomedical companies, totalling $11,786.25, including $3,991.25 from  AstraZeneca UK Limited
    Subjects: Anaplastic Lymphoma Kinase; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
    Categories: Genetics
    Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. (2019)
    Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. (2015)

  9. Folpe, Andrew L   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. . Top Hospital
    Physician 
    Medical school: University of Rochester School of Medicine and Dentistry (MD, 1994)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Hematologic Neoplasms; Leiomyosarcoma; Lymphoma, Large B-Cell, Diffuse; Rhabdomyosarcoma
    Response to Lee et al: Toward a unifying entity that encompasses most, but perhaps not all, inflammatory leiomyosarcomas and histiocyte-rich rhabdomyoblastic tumors. (2021)
    Inflammatory rhabdomyoblastic tumor with progression to high-grade rhabdomyosarcoma. (2021)

  10. Loghavi, Sanam   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments from biomedical company (Servier Pharmaceuticals LLC) in 2021 for $154.86
    Subjects: Breast; Hematologic Neoplasms; Lymphoma
    Categories: Pathology
    Unusual breast mass: lymphoma with crystal-storing histiocytosis. (2015)
    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. (2022)

  11. Ulaner, Gary A   Diagnostic Radiology  Google Publications
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 84.8/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $15,108.92, including $15,108.92 from  GE HEALTHCARE
    Subjects: Histiocytic Disorders, Malignant; Anaplastic Lymphoma Kinase; Azetidines; Imidazoles; Mitogen-Activated Protein Kinase Kinases
    Categories: Genetics; Therapeutic Use; Drug Therapy; Enzymology; Antagonists & Inhibitors
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)
    Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. (2019)

  12. Arend, Lois J   Anatomic Pathology   Google Publications
    Renal Pathology, Department of Pathology, Johns Hopkins University and Johns Hopkins Hospital, Baltimore, MD 21287, USA. Electronic address: . Top Hospital
    Physician  Case Reports 
    Medical school: Other (MD, 1992)
    Medicare Accepted
    Subjects: Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Kidney; Kidney Glomerulus; Paraproteinemias
    Categories: Pathology; Complications; Ultrastructure
    Renal crystal-storing histiocytosis involving glomeruli - A comprehensive clinicopathologic analysis. (2019)
    Crystal-storing histiocytosis. (2016)

  13. Tahan, Steven R   Anatomic Pathology  Google Publications
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Top Hospital
    Physician  Case Reports 
    Medical school: Yale University School of Medicine (MD, 1979)
    Medicare Accepted
    Subjects: Cellulitis; Histiocytes; Lymphatic Diseases; Lymphatic Vessels; Osteoarthritis
    Categories: Complications; Pathology; Diagnosis; Physiology
    Intralymphatic histiocytosis in healing cellulitis: Case report and review of the literature. (2020)
    Intralymphatic histiocytosis in association with severe osteoarthritis of the shoulder. (2013)

  14. Kim, Jinah   Dermatopathology  Google Publications
    Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 74/100
    Disclosed payments from biomedical company (Regeneron Healthcare Solutions, Inc.) in 2021 for $99.99
    Subjects: Biomarkers, Tumor; Dendritic Cells; Melanoma; Myeloid Cells; SOXE Transcription Factors
    Categories: Metabolism; Diagnosis
    Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. (2012)
    Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin. (2018)

  15. Bagg, Adam   Clinical Pathology/Laboratory Medicine  Google Publications
    Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; and. Top Hospital
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 78/100
    Subjects: Bone Marrow; Bone Marrow Examination; Head and Neck Neoplasms; Histiocytes; Immunoglobulin Light Chains
    Categories: Diagnosis; Pathology; Analysis; Chemistry; Ultrastructure
    Crystal-storing histiocytosis in plasma cell myeloma. (2010)
    Leukemia Cutis With Histopathologic and Immunophenotypic Features Resembling S100-Negative CD1a-Positive Cutaneous Histiocytosis. (2021)

  16. Natkunam, Yasodha   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 65/100
    Disclosed payments in 2021 from 2 biomedical companies, totalling $2,977.5, including $1,977.5 from  Genentech, Inc.
    Subjects: Dendritic Cells; Hematologic Neoplasms; Myeloid Cells; Transcription Factors
    Categories: Metabolism; Diagnosis
    Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin. (2018)
    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. (2022)

  17. Abdel-Wahab, Omar     Google Publications
    Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. . Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Subjects: Histiocytic Disorders, Malignant; Mutation; Proto-Oncogene Proteins B-raf; Anaplastic Lymphoma Kinase; Azetidines
    Categories: Genetics; Therapeutic Use; Drug Therapy; Enzymology; Antagonists & Inhibitors
    Efficacy of MEK inhibition in patients with histiocytic neoplasms. (2019)
    Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. (2019)

  18. Puzanov, Igor   Hematology & Oncology  Google Publications
    Physician  Clinical Trial 
    Medical school: Other (MD, 1991)
    Medicare Accepted
    Disclosed payments in 2021 from 6 biomedical companies, totalling $4,827.62, including $3,078.5 from  Regeneron Pharmaceuticals, Inc.
    Subjects: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Indoles; Mutation; Neoplasms
    Categories: Drug Therapy; Therapeutic Use; Genetics
    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015)

  19. Raje, Noopur S   Internal Medicine  Google Publications
    Physician  Clinical Trial 
    Medical school: Other (MD, 1992)
    Medicare Accepted
    Disclosed payments in 2021 from 31 biomedical companies, totalling $59,113.42, including $12,500 from  E.R. Squibb & Sons, L.L.C.
    Subjects: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Indoles; Mutation; Neoplasms
    Categories: Drug Therapy; Therapeutic Use; Genetics
    Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015)

  20. Berliner, Nancy   Hematology   Google Publications
    Editor-in-Chief, Blood.
    Physician 
    Medical school: Yale University School of Medicine (MD, 1979)
    Medicare Accepted
    Disclosed payments from biomedical company (AstraZeneca UK Limited) in 2021 for $304.71
    Subjects: Macrophage Activation Syndrome; Hematologic Diseases; Lymphoproliferative Disorders; Mastocytosis, Systemic
    Categories: Diagnosis; Etiology; Therapy
    Introduction to a review series on rare systemic hematologic disorders. (2020)
    Congenital and Acquired Disorders of Macrophages and Histiocytes. (2015)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);